Cancer　invasion　and　metastasis,　remain　the　major　causes　of　over　90%　of　patient　deaths.　Molecular　imaging　methods　such　as　computed　tomography　(CT)/magnetic　resonance　imaging　(MRI)　can　precisely　assess　primary　regional　lymph　node　invasion　and　distant　organ　metastasis　via　body　scanning;　however,　such　diagnostic　methods　are　often　utilized　too　late　for　cancer　therapy.　To　date,　pathologic　methods　mainly　provide　information　on　differentiation/proliferation　and　potential　drug　therapy　biomarkers　of　primary　tumors　rather　than　precisely　reveal　tumor　regional　invasion　and　distant　metastasis　in　the　body.　We　hypothesized　that　quantification　of　membrane　type-1　matrix　metalloproteinase　(MT1-MMP)　levels　in　primary　tumor　tissue　will　provide　a　precise　assessment　of　tumor　regional　lymph　node　invasion　and　remote　organ　metastasis.　In　this　work,　we　developed　peptide-coated　Au　clusters　with　intrinsic　red　fluorescence　and　a　specific　mass　signal.　When　these　clusters　labeled　MT1-MMP　in　tumor　tissue　sections　derived　from　the　xenograft　lung　carcinoma　model,　human　lung　carcinoma　and　human　renal　carcinoma,　we　could　directly　observe　MT1-MMP　via　optical　fluorescence　microscopy　and　quantitatively　detect　the　MT1-MMP　expression　level　via　laser　ablation　inductively　coupled　plasma　mass　spectrometry　2D　mapping　(2D-LA-Mass　Mapping).　By　observing　and　quantifying　the　MT1-MMP　expression　level　in　primary　human　lung　carcinoma　and　human　renal　carcinoma　tissue　sections,　we　precisely　assessed　the　risk　of　primary　tumor　invasion/metastasis.　Importantly,　the　accuracy　of　this　pathologic　method　was　verified　by　CT/MRI　molecular　imaging　of　cancer　patients　and　traditional　hematoxylin　and　eosin　(H&E)　staining/immunohistochemistry　(IHC)/immunofluorescence　(IF)　pathologic　studies　of　primary　tumor　tissues.